Sitemap | Contact Us  

Welcome To Taj Pharmaceuticals Ltd API      

About Worldwide  |     FAQs    |    Careers     | |        Media Center  |  |    Taj Pharmaceuticals  World   | |     TAJ Group 

HOME >> API >> API List 3 >> Pamidronate Disodium >> Dosage

DOSAGE
Pamidronate Disodium  CAS Number 109552-15-0

Paget's Disease

Pamidronate Disodium is indicated for the treatment of patients with moderate to severe Paget's disease of bone. The effectiveness of Pamidronate Disodium was demonstrated primarily in patients with serum alkaline phosphatase ≥ 3 times the upper limit of normal. Pamidronate Disodium therapy in patients with Paget's disease has been effective in reducing serum alkaline phosphatase and urinary hydroxyproline levels by ≥ 50% in at least 50% of patients, and by ≥ 30% in at least 80% of patients. Pamidronate Disodium therapy has also been effective in reducing these biochemical markers in patients with Paget's disease who failed to respond, or no longer responded to other treatments.
Osteolytic Bone Metastases of Breast Cancer and Osteolytic Lesions of Multiple Myeloma

Pamidronate Disodium is indicated, in conjunction with standard antineoplastic therapy, for the treatment of osteolytic bone metastases of breast cancer and osteolytic lesions of multiple myeloma. The Pamidronate Disodium treatment effect appeared to be smaller in the study of breast cancer patients receiving hormonal therapy than in the study of those receiving chemotherapy, however, overall evidence of clinical benefit has been demonstrated.

Paget Disease

Adults

IV 30 mg/day as a 4-h infusion on 3 consecutive days for a total dose of 90 mg. For retreatment, same as initial therapy, when clinically indicated.
Osteolytic Bone Metastases of Breast Cancer

Adults

IV 90 mg as a 2-h infusion every 3 to 4 wk.
Osteolytic Bone Lesions of Multiple Myeloma
Adults

IV 90 mg as a 4-h infusion on a monthly basis. General Advice

* For IV administration only. Not for intradermal, subcutaneous, IM, intra-arterial, or oral administration.
* Concentrated injection solution must be further diluted before administration.
* Reconstitute lyophilized powder with 10 mL sterile water for injection. Allow drug to dissolve completely before withdrawing for further dilution.
* Do not administer if particulate matter or discoloration noted.
* Administer diluted solution via separate IV line.

Hypercalcemia of malignancy

* Dilute the recommended dose in 1,000 mL 0.45% or sodium chloride 0.9% or dextrose 5% injection. Infuse prescribed dose over 2 to 24 h as ordered.

Paget disease

* Dilute the recommended dose in 500 mL 0.45% or sodium chloride 0.9% or dextrose 5% injection. Infuse prescribed dose over 4 h.

Osteolytic bone lesions of multiple myeloma

* Dilute the recommended dose in 500 mL 0.45% or sodium chloride 0.9% or dextrose 5% injection. Infuse prescribed dose over 4 h.

Osteolytic bone metastases of breast cancer

* Dilute the recommended dose in 500 mL 0.45% or sodium chloride 0.9% or dextrose 5% injection. Infuse prescribed dose over 2 h.

Information Associated with Product:
DRUG DESCRIPTION DOSAGE >> SIDE EFFECTS PRECAUTIONS INTERACTION CONSUMER INFORMATION
PDF DOWNLOAD	WORD DOCUMENT
Product Enquiry Product Quotation Sample Request Place Your Order

Investor Relations    Feedback     Contact Worldwide    Sitemap